Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Irish biotech collects $75M in Series B to start Phase 3 rare joint tumor trial

SynOx Therapeutics has completed a $75 million Series B raise to advance its monoclonal antibody drug through a registrational trial for a type of non-cancerous

April 23, 2024

Janssen’s BALVERSA gets EC approval for urothelial carcinoma

In a Phase III trial, erdafitinib treatment showed a median progression-free survival of 5.6 months versus 2.7 months for chemotherapy. Credit: MattL_Images/Shutterstock. The European Commission

August 26, 2024

Study finds psychotherapy as effective treatment for PTSD patients after multiple traumatic events

Psychotherapy is an effective treatment for adults with post-traumatic stress disorder (PTSD) following exposure to multiple traumatic events, according to new research from the University

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.